Ronald L Cowan1. 1. Psychiatric Neuroimaging Program, Department of Psychiatry, Vanderbilt University Medical Center, 1500 21st Avenue South, Suite 3000, Nashville, TN 37212, USA. Ronald.L.Cowan@Vanderbilt.edu
Abstract
RATIONALE: Determining whether, under what circumstances, and to what extent 3,4-methylenedioxymethamphetamine (MDMA) exposure produces chronic changes in human brain function is a critical public health issue. MDMA is a widely used recreational drug commonly sold as "Ecstasy". Because findings from the animal literature have indicated that specific dosage regimens of MDMA can produce long-lasting alterations in serotonergic function, existing studies of MDMA effects in humans have examined brain serotonin (5-HT) transporters (5-HTT) and receptors or have examined brain structures or functions potentially affected by MDMA. OBJECTIVES: The objectives of this review are to provide a background for interpreting human MDMA neuroimaging research, to examine existing neuroimaging data regarding the rationale for and limitations to human MDMA research, and to provide suggestions for improving the design and interpretation of future neuroimaging approaches. RESULTS: Of the existing neuroimaging studies in human MDMA users, few experimental designs have been replicated across different research groups. Only investigations employing nuclear imaging methods to assay brain 5-HTT levels have been replicated across methods and research laboratories. These studies have found reduced levels of the 5-HTT in recently abstinent MDMA users with some evidence for normalization of 5-HTT levels with prolonged abstinence. However, the sensitivity of these methods is unknown. CONCLUSIONS: The current state of neuroimaging in human MDMA users does not permit conclusions regarding the long-term effects of MDMA exposure. Future study designs might benefit from improved sample homogeneity, increased length of MDMA abstinence, longitudinal study design, test-retest measures, serotonergic specificity, and multimodal approaches.
RATIONALE: Determining whether, under what circumstances, and to what extent 3,4-methylenedioxymethamphetamine (MDMA) exposure produces chronic changes in human brain function is a critical public health issue. MDMA is a widely used recreational drug commonly sold as "Ecstasy". Because findings from the animal literature have indicated that specific dosage regimens of MDMA can produce long-lasting alterations in serotonergic function, existing studies of MDMA effects in humans have examined brain serotonin (5-HT) transporters (5-HTT) and receptors or have examined brain structures or functions potentially affected by MDMA. OBJECTIVES: The objectives of this review are to provide a background for interpreting humanMDMA neuroimaging research, to examine existing neuroimaging data regarding the rationale for and limitations to humanMDMA research, and to provide suggestions for improving the design and interpretation of future neuroimaging approaches. RESULTS: Of the existing neuroimaging studies in humanMDMA users, few experimental designs have been replicated across different research groups. Only investigations employing nuclear imaging methods to assay brain 5-HTT levels have been replicated across methods and research laboratories. These studies have found reduced levels of the 5-HTT in recently abstinent MDMA users with some evidence for normalization of 5-HTT levels with prolonged abstinence. However, the sensitivity of these methods is unknown. CONCLUSIONS: The current state of neuroimaging in humanMDMA users does not permit conclusions regarding the long-term effects of MDMA exposure. Future study designs might benefit from improved sample homogeneity, increased length of MDMA abstinence, longitudinal study design, test-retest measures, serotonergic specificity, and multimodal approaches.
Authors: Liesbeth Reneman; Jan Booij; Jan B A Habraken; Kora De Bruin; George Hatzidimitriou; Gerard J Den Heeten; George A Ricaurte Journal: Synapse Date: 2002-12-01 Impact factor: 2.562
Authors: Ronald L Cowan; In Kyoon Lyoo; Seung Mo Sung; Kyung Heup Ahn; Minue J Kim; Jaeuk Hwang; Erika Haga; Ram Lakhan Panday Vimal; Scott E Lukas; Perry F Renshaw Journal: Drug Alcohol Depend Date: 2003-12-11 Impact factor: 4.492
Authors: Christina R Di Iorio; Tristan J Watkins; Mary S Dietrich; Aize Cao; Jennifer U Blackford; Baxter Rogers; Mohammed S Ansari; Ronald M Baldwin; Rui Li; Robert M Kessler; Ronald M Salomon; Margaret Benningfield; Ronald L Cowan Journal: Arch Gen Psychiatry Date: 2011-12-05
Authors: John Karageorgiou; Mary S Dietrich; Evonne J Charboneau; Neil D Woodward; Jennifer U Blackford; Ronald M Salomon; Ronald L Cowan Journal: Neuroimage Date: 2009-03-02 Impact factor: 6.556
Authors: Ronald L Cowan; Nicolas R Bolo; Mary Dietrich; Erica Haga; Scott E Lukas; Perry F Renshaw Journal: Psychiatry Res Date: 2007-06-18 Impact factor: 3.222
Authors: Gerry Jager; Maartje M de Win; Hylke K Vervaeke; Thelma Schilt; Rene S Kahn; Wim van den Brink; Jan M van Ree; Nick F Ramsey Journal: Psychopharmacology (Berl) Date: 2007-05-03 Impact factor: 4.530